074430.KQ Aminologics Co.Ltd
- Market cap
- KRW 88.9B
- P/E
- -
- P/B
- 1.52x
- ROE
- 7.0%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 074430.KQ undervalued?
Graham numberThe Graham number of Aminologics Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aminologics Co.Ltd fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (7.0%), below 10%.
ROA 0/1
Return on assets (4.6%) is below the industry median (4.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (317.4%) is above the 5-year average (10.5% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (317.4%) is above the industry median (-16.9%).
Revenue Growth 0/2
Revenue shrank 7.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 4.4x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.5x) is above the industry median (0.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aminologics Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D-leucine, D-valine, 4-chloro-L-phenylalanine, D-histidine, Fmoc-D-allo-isoleucin…
Full company profileAminologics Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aminologics Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.4B | 16.8B | 18.4B | 19.0B | 17.7B | 22.8B | 27.3B | 20.9B | 16.8B | 22.0B | 27.3B |
| Gross Profit | 4.41B | 3.89B | 7.08B | 3.29B | 6.99B | 9.14B | 12.8B | 7.78B | 3.42B | 9.86B | 12.6B |
| Operating Income | -4.00B | 315M | 4.18B | -761M | 2.48B | 2.57B | -6.48B | 1.46B | -3.14B | 3.59B | 5.23B |
| EBITDA | - | - | - | - | - | - | -5.89B | 2.79B | -556M | 4.99B | 9.29B |
| Net Income | -3.74B | 542M | 8.00B | -1.20B | 2.14B | 5.36B | -7.28B | 2.44B | -1.62B | 3.52B | 4.11B |
| EPS | -43 | 6.17 | 91 | -14 | 24 | 61 | -83 | 28 | -18 | 40 | 47 |
| Balance Sheet | |||||||||||
| Total Assets | 49.0B | 49.4B | 56.9B | 57.8B | 60.1B | 65.2B | 55.6B | 57.7B | 56.8B | 84.2B | 89.7B |
| Total Liabilities | 4.48B | 4.23B | 3.67B | 5.92B | 6.57B | 5.85B | 4.18B | 3.26B | 5.09B | 28.2B | 31.3B |
| Shareholders' Equity | 44.5B | 45.1B | 53.2B | 51.9B | 53.6B | 59.4B | 51.4B | 54.4B | 51.7B | 56.0B | 58.4B |
| Cash & Short-term Investments | 14.7B | 17.5B | 21.9B | 24.7B | 25.4B | 25.7B | 29.2B | 28.5B | 35.4B | 26.5B | 23.1B |
| Total Debt | - | - | - | 1.68B | 1.52B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.14B | 3.00B | 4.56B | 3.60B | 1.77B | 936M | 5.23B | -218M | 7.47B | 2.54B | 8.73B |
| Capital Expenditure | 1.14B | 204M | 231M | 100M | 309M | 516M | 503M | 156M | 512M | 45.7M | 60.0M |
| Free Cash Flow | - | - | - | - | 1.40B | 274M | 4.72B | -374M | 6.95B | 2.49B | 8.67B |
| Ratios | |||||||||||
| ROE | -8.4% | 1.2% | 15.0% | -2.3% | 4.0% | 9.0% | -14.2% | 4.5% | -3.1% | 6.3% | 7.0% |
| ROA | -7.6% | 1.1% | 14.1% | -2.1% | 3.6% | 8.2% | -13.1% | 4.2% | -2.9% | 4.2% | 4.6% |
| Net Profit Margin | -22.9% | 3.2% | 43.3% | -6.3% | 12.1% | 23.5% | -26.6% | 11.7% | -9.6% | 16.0% | 15.1% |
| Debt to Equity | - | - | - | 0.03x | 0.03x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aminologics Co.Ltd dividends
Aminologics Co.Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 797:732 on May 4, 2011.
Who owns Aminologics Co.Ltd
- Insiders 31.42%
- Institutions 0.49%
- Public & others 68.09%
- Shares outstanding 94.1M
- Free float 60.2M
Aminologics Co.Ltd company profile
- Company name
- Aminologics Co.Ltd
- Ticker
- 074430.KQ
- ISIN
- KR7074430000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 36
- Fiscal year end
- December
- Address
- Samoh Building, Seoul, South Korea, 135-925
- Phone
- 82 2 761 4570
- Website
- aminologics.co.kr
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D-leucine, D-valine, 4-chloro-L-phenylalanine, D-histidine, Fmoc-D-allo-isoleucine, Fmoc-D-alanine, and Fmoc-D-phenylalanine. The company's products also comprise Boc-D-phenylalanine, L-homophenylalanine, D-homophenylalanine, 3-(3-pyridyl)-L-alanine, 3-(3-pyridyl)-D-alanine, D-cysteine HCL H2O, D-serine methyl ester HCl, Boc-D-Ser-OH, D-threonine, Fmoc-D-Leu-OH, Boc-D-4-Benzoylphenylalanine, Fmoc-D-Cyclohexylalanine, Fmoc-D-Pentafluorophenylalanine, Fmoc-D-Trp(Boc)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-D-Ser(tBu)-OH, and Fmoc-L-Ser(tBu)-OH. In addition, it operates resort and power generation businesses. Aminologics Co.,Ltd. was founded in 1997 and is headquartered in Seoul, South Korea.
Aminologics Co.Ltd management
4- Mr. Hun-Yeol Hun YunChief Exec. Officer · born 1962
- Kyung-II KimPres · born 1958
- Won-Sup KimSr. Managing Director and Director of Marketing Division · born 1959
- Jae-Gwan LeeManaging Director · born 1959